Article Text

Download PDFPDF

1103 A national retrospective study on efficacy of adjuvant (chemo)radiotherapy for vulvar cancer
  1. C Casà1,
  2. G Macchia2,
  3. M Ferioli3,
  4. V Lancellotta1,
  5. M Boccardi2,
  6. A Cerrotta4,
  7. F Tortoreto5,
  8. E Ippolito6,
  9. C Laliscia7,
  10. A Huscher8,
  11. JDI Muzio9,
  12. AG Morganti3,
  13. R Lazzari10,
  14. G Ferrandina11 and
  15. L Tagliaferri1
  1. 1Fondazione Policlinico Universitario A. Gemelli IRCCS, Dipartimento di Diagnostica per Immagini, Radioterapia Oncologica ed Ematologia, Rome, Italy
  2. 2Gemelli Molise Hospital – Università Cattolica del Sacro Cuore, Radiation Oncology Unit, Campobasso, Italy
  3. 3IRCCS Azienda Ospedaliero-Universitaria di Bologna – Alma Mater Studiorum University of Bologna, Radiation Oncology, Department of Experimental, Diagnostic and Specialty Medicine – DIMES, Bologna, Italy
  4. 4Fondazione IRCCS Istituto Nazionale dei Tumori, Radiotherapy Unit, Milan, Italy
  5. 5Ospedale San Pietro Fatebenefratelli, Radiotherapy Unit, Rome, Italy
  6. 6Università Campus Bio-Medico, Radiation Oncology, Rome, Italy
  7. 7University of Pisa, Department of New Technologies and Translational Research, Division of Radiation Oncology, Pisa, Italy
  8. 8Fondazione Poliambulanza, U.O. di Radioterapia Oncologica “Guido Berlucchi”, Brescia, Italy
  9. 9A.O.U “Città della Salute e della Scienza”, Dipartimento di Oncologia P.O. S. Anna – SS Radioterapia, Turin, Italy
  10. 10IEO European Institute of Oncology IRCCS, Division of Radiotherapy, Milan, Italy
  11. 11Fondazione Policlinico Universitario A. Gemelli, IRCCS – Università Cattolica del Sacro Cuore, Unità Operativa Complessa Ginecologia Oncologica, Dipartimento per la Salute della Donna e del Bambino e della Salute Pubblica, Rome, Italy


Introduction/Background*Vulvar cancer (VC) is a rare gynaecologic malignancy. The study aims to evaluate in a retrospective, multicentred, real-world dataset of patients affected by VC efficacy and safety of adjuvant (chemo)radiotherapy (aRT), focusing especially to the treatment prescription among participant centers joining the Observational itaLian stuDy on vuLvar cAncer adjuvant raDiotherapY (OLDLADY) project endorsed by the GYN study group of the AIRO (Italian Association of Radiotherapy and Clinical Oncology).

Methodology Patients affected by VC and treated by eRT from January 2010 to December 2018 in Nine Italian radiotherapy centers were retrospectively included and clinical data were collected, analysing tumour staging, treatment prescription, clinical and toxicity outcomes.

Result(s)*The multicentred retrospective cohort was composed by 181 patients (patient populations shown in table 1), with a median age of 71.5 years (range 17-90). A considerable heterogeneity was found in the treatment prescription, radiotherapy doses and concomitant chemotherapy schedules. The most relevant acute toxicity revealed for the patient cohort was skin toxicity (22.1%); instead, the rate of severe chronic lymphoedema was 1.1%. After a median follow-up of 30 months (range 1-185), the 2-year actuarial local control rate (LC), the 2-year disease free survival rate (DFS) and the overall survival rate (OS) were 57.2%, 49.4%, and 55.1%, respectively. Kaplan-Meier curves were computed and reported in figure 1.

Abstract 1103 Table 1

Study population

Abstract 1103 Figure 1

Kaplan meier curves for LC, DFS and OS

Conclusion*A diverse spectrum of radiotherapy options to exclusively treat patients affected by VC was reported. To achieve higher treatment standardisation, in terms of prescribed doses and volumes, this study suggest further cooperative prospective studies.

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.